Dosing & Uses
Dosage Forms & Strengths
injection, lyophylized powder
- 750mg/vial
Skin & Skin Structure Infections
Indicated for skin and skin structure infections caused by Gram-positive bacteria including Staphylococcus aureus (including methicillin-resistant and methicillin-susceptible strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (includes S anginosus, S intermedius, and S constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates only)
10 mg/kg IV q24hr for 7-14 days; infuse over 1 hr
Pneumonia
Indicated for hospital-acquired, including ventilator-associated bacterial pneumonia caused by susceptible isolates of Staphylococcus aureus (including methacillin-relesistant and vancomycin-intermediate strains) when alternative treatments are not suitable
10 mg/kg IV q24hr for 7-21 days; infuse over 1 hr
Dosage Modifications
Renal impairment
- CrCl 30-50 mL/minute: 7.5 mg/kg IV q24hr
- CrCl 10-29 mL/minute: 10 mg/kg IV q48hr
Dosing Considerations
Pneumonia: Approved only to treat Staphylococcus aureus, not other pneumonia-causing bacteria
Safety and efficacy not established
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (49)
- adagrasib
adagrasib, telavancin. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.
- amiodarone
amiodarone and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- anagrelide
anagrelide and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- arsenic trioxide
arsenic trioxide and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- artemether
artemether and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- asenapine
asenapine and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- asenapine transdermal
asenapine transdermal and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine
buprenorphine and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine buccal
buprenorphine buccal and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine subdermal implant
buprenorphine subdermal implant and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine transdermal
buprenorphine transdermal and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine, long-acting injection
buprenorphine, long-acting injection and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- ceritinib
ceritinib and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- cholera vaccine
telavancin, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.
- desflurane
desflurane and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- disopyramide
disopyramide and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- encorafenib
encorafenib and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- entrectinib
telavancin and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.
- eribulin
eribulin and telavancin both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- fexinidazole
fexinidazole and telavancin both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.
- glasdegib
telavancin and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.
- hydroxychloroquine sulfate
hydroxychloroquine sulfate and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- ibutilide
ibutilide and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- indapamide
indapamide and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- inotuzumab
inotuzumab and telavancin both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.
- isoflurane
isoflurane and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- ivosidenib
ivosidenib and telavancin both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.
- lefamulin
lefamulin and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- macimorelin
macimorelin and telavancin both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.
- microbiota oral
telavancin decreases effects of microbiota oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Microbiota oral contains bacterial spores. Antibacterial agents may decrease efficacy if coadministered. Complete antibiotic regimens 2-4 days before initiating microbiota oral. .
- ondansetron
ondansetron and telavancin both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.
- oxaliplatin
oxaliplatin and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- panobinostat
telavancin and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.
- pentamidine
pentamidine and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- pimozide
pimozide and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- pitolisant
telavancin and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.
- procainamide
procainamide and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- quinidine
quinidine and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- ribociclib
ribociclib increases toxicity of telavancin by QTc interval. Avoid or Use Alternate Drug.
- saquinavir
saquinavir, telavancin. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug.
- sevoflurane
sevoflurane and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- siponimod
siponimod and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- sotalol
sotalol and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- tacrolimus
tacrolimus and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- tetrabenazine
tetrabenazine and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
- umeclidinium bromide/vilanterol inhaled
telavancin increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
- vandetanib
telavancin, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.
- vemurafenib
vemurafenib and telavancin both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.
- vilanterol/fluticasone furoate inhaled
telavancin increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
Monitor Closely (123)
- albuterol
albuterol and telavancin both increase QTc interval. Use Caution/Monitor.
- alfuzosin
telavancin and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and telavancin both increase QTc interval. Use Caution/Monitor. - amisulpride
amisulpride and telavancin both increase QTc interval. Modify Therapy/Monitor Closely. ECG monitoring is recommended if coadministered.
- amitriptyline
amitriptyline and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- amoxapine
amoxapine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- apomorphine
apomorphine and telavancin both increase QTc interval. Use Caution/Monitor.
- arformoterol
arformoterol and telavancin both increase QTc interval. Use Caution/Monitor.
- aripiprazole
aripiprazole and telavancin both increase QTc interval. Use Caution/Monitor.
- artemether/lumefantrine
artemether/lumefantrine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- atomoxetine
atomoxetine and telavancin both increase QTc interval. Use Caution/Monitor.
- bedaquiline
telavancin and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely
- chlorpromazine
chlorpromazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- ciprofloxacin
ciprofloxacin and telavancin both increase QTc interval. Use Caution/Monitor. Ciprofloxacin elicits minimal effects on QT interval. Caution if used in combination with other drugs known to affect QT interval or in patients with other risk factors.
- citalopram
telavancin and citalopram both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
- clarithromycin
clarithromycin and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- clomipramine
clomipramine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- clozapine
clozapine and telavancin both increase QTc interval. Use Caution/Monitor.
- crizotinib
crizotinib and telavancin both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
- dasatinib
dasatinib and telavancin both increase QTc interval. Use Caution/Monitor.
- degarelix
degarelix and telavancin both increase QTc interval. Use Caution/Monitor.
- desipramine
desipramine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- deutetrabenazine
deutetrabenazine and telavancin both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).
- dofetilide
dofetilide and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- dolasetron
dolasetron and telavancin both increase QTc interval. Use Caution/Monitor.
- donepezil
donepezil and telavancin both increase QTc interval. Use Caution/Monitor.
- doxepin
doxepin and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- dronedarone
dronedarone and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- droperidol
droperidol and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- efavirenz
efavirenz and telavancin both increase QTc interval. Use Caution/Monitor.
- eliglustat
eliglustat and telavancin both increase QTc interval. Use Caution/Monitor.
- epinephrine
epinephrine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- epinephrine racemic
epinephrine racemic and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- erythromycin base
erythromycin base and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- erythromycin ethylsuccinate
erythromycin ethylsuccinate and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- erythromycin lactobionate
erythromycin lactobionate and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- erythromycin stearate
erythromycin stearate and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- escitalopram
escitalopram increases toxicity of telavancin by QTc interval. Use Caution/Monitor.
- ezogabine
ezogabine, telavancin. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.
- fingolimod
fingolimod and telavancin both increase QTc interval. Use Caution/Monitor.
- flecainide
flecainide and telavancin both increase QTc interval. Use Caution/Monitor.
- fluconazole
fluconazole and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- fluoxetine
fluoxetine and telavancin both increase QTc interval. Use Caution/Monitor.
- fluphenazine
fluphenazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- fluvoxamine
fluvoxamine and telavancin both increase QTc interval. Use Caution/Monitor.
- formoterol
formoterol and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- foscarnet
foscarnet and telavancin both increase QTc interval. Use Caution/Monitor.
- fostemsavir
telavancin and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.
- gemifloxacin
gemifloxacin and telavancin both increase QTc interval. Use Caution/Monitor.
- gemtuzumab
telavancin and gemtuzumab both increase QTc interval. Use Caution/Monitor.
- gilteritinib
gilteritinib and telavancin both increase QTc interval. Use Caution/Monitor.
- goserelin
goserelin increases toxicity of telavancin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- granisetron
granisetron and telavancin both increase QTc interval. Use Caution/Monitor.
- haloperidol
haloperidol and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- histrelin
histrelin increases toxicity of telavancin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- hydroxyzine
hydroxyzine and telavancin both increase QTc interval. Use Caution/Monitor.
- iloperidone
iloperidone and telavancin both increase QTc interval. Use Caution/Monitor.
- imipramine
imipramine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- indacaterol, inhaled
indacaterol, inhaled, telavancin. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.
- itraconazole
itraconazole and telavancin both increase QTc interval. Use Caution/Monitor.
- ketoconazole
ketoconazole and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- lapatinib
lapatinib and telavancin both increase QTc interval. Use Caution/Monitor.
- lenvatinib
telavancin and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.
- leuprolide
leuprolide increases toxicity of telavancin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- levofloxacin
levofloxacin and telavancin both increase QTc interval. Use Caution/Monitor.
- levoketoconazole
levoketoconazole and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- lithium
lithium and telavancin both increase QTc interval. Use Caution/Monitor.
- lofepramine
lofepramine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- lumefantrine
lumefantrine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- maprotiline
maprotiline and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- methadone
methadone and telavancin both increase QTc interval. Use Caution/Monitor.
- mifepristone
mifepristone, telavancin. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.
- mirtazapine
mirtazapine and telavancin both increase QTc interval. Use Caution/Monitor.
- moxifloxacin
moxifloxacin and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- nilotinib
nilotinib and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- nortriptyline
nortriptyline and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- octreotide
octreotide and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- octreotide (Antidote)
octreotide (Antidote) and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- ofloxacin
ofloxacin and telavancin both increase QTc interval. Use Caution/Monitor.
- olanzapine
olanzapine and telavancin both increase QTc interval. Use Caution/Monitor.
- olodaterol inhaled
telavancin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias
- osilodrostat
osilodrostat and telavancin both increase QTc interval. Use Caution/Monitor.
- osimertinib
osimertinib and telavancin both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.
- oxaliplatin
oxaliplatin will increase the level or effect of telavancin by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.
- ozanimod
ozanimod and telavancin both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.
- paliperidone
paliperidone and telavancin both increase QTc interval. Use Caution/Monitor.
- paroxetine
paroxetine and telavancin both increase QTc interval. Use Caution/Monitor.
- pasireotide
telavancin and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.
- perphenazine
perphenazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- posaconazole
posaconazole and telavancin both increase QTc interval. Use Caution/Monitor.
- primaquine
primaquine and telavancin both increase QTc interval. Use Caution/Monitor.
- prochlorperazine
prochlorperazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- promazine
promazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- promethazine
promethazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- protriptyline
protriptyline and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- quetiapine
quetiapine, telavancin. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
- quinine
telavancin and quinine both increase QTc interval. Use Caution/Monitor.
- quizartinib
quizartinib, telavancin. Either increases effects of the other by QTc interval. Modify Therapy/Monitor Closely. Monitor patients more frequently with ECG if coadministered with QT prolonging drugs.
- ranolazine
ranolazine and telavancin both increase QTc interval. Use Caution/Monitor.
- rilpivirine
rilpivirine increases toxicity of telavancin by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsade de Pointes.
- risperidone
risperidone and telavancin both increase QTc interval. Use Caution/Monitor.
- romidepsin
romidepsin and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- selpercatinib
selpercatinib increases toxicity of telavancin by QTc interval. Use Caution/Monitor.
- sertraline
sertraline and telavancin both increase QTc interval. Use Caution/Monitor.
- sodium picosulfate/magnesium oxide/anhydrous citric acid
telavancin decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug.
- solifenacin
solifenacin and telavancin both increase QTc interval. Use Caution/Monitor.
- sorafenib
sorafenib and telavancin both increase QTc interval. Use Caution/Monitor.
- sulfamethoxazole
sulfamethoxazole and telavancin both increase QTc interval. Use Caution/Monitor.
- sunitinib
sunitinib and telavancin both increase QTc interval. Use Caution/Monitor.
- tenofovir DF
telavancin, tenofovir DF. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Use Caution/Monitor.
telavancin increases levels of tenofovir DF by decreasing renal clearance. Use Caution/Monitor. - thioridazine
thioridazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- trazodone
trazodone and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- trifluoperazine
trifluoperazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- trimethoprim
telavancin and trimethoprim both increase QTc interval. Use Caution/Monitor.
- trimipramine
trimipramine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- triptorelin
triptorelin increases toxicity of telavancin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- tropisetron
telavancin and tropisetron both increase QTc interval. Use Caution/Monitor.
- valbenazine
valbenazine and telavancin both increase QTc interval. Use Caution/Monitor.
- venlafaxine
telavancin and venlafaxine both increase QTc interval. Use Caution/Monitor.
- voclosporin
voclosporin, telavancin. Either increases effects of the other by QTc interval. Use Caution/Monitor.
- voriconazole
telavancin and voriconazole both increase QTc interval. Use Caution/Monitor.
- vorinostat
vorinostat and telavancin both increase QTc interval. Use Caution/Monitor.
- warfarin
telavancin increases effects of warfarin by anticoagulation. Use Caution/Monitor.
- ziprasidone
telavancin and ziprasidone both increase QTc interval. Modify Therapy/Monitor Closely.
Minor (4)
- azithromycin
azithromycin and telavancin both increase QTc interval. Minor/Significance Unknown.
- chloroquine
chloroquine increases toxicity of telavancin by QTc interval. Minor/Significance Unknown.
- entecavir
telavancin, entecavir. Either increases effects of the other by decreasing renal clearance. Minor/Significance Unknown. Coadministration with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.
- pazopanib
pazopanib and telavancin both increase QTc interval. Minor/Significance Unknown.
Adverse Effects
>10%
Taste disturbance
Nausea
Vomiting
Foamy urine
1-10%
Diarrhea
Dizziness
Rigors
Pruritus
Rash
Warnings
Black Box Warnings
Renal impairment
- Increased mortality compared with vancomycin in patients with pre-existing moderate/severe renal impairment (CrCl 50 mL/min or less) who were treated for hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia
- Use with pre-existing moderate/severe renal impairment should be considered only when the anticipated benefit to the patient outweighs the potential risk
- Nephrotoxicity: New onset or worsening renal impairment has occurred; monitor renal function in all patients
Pregnancy
- Women of childbearing potential should have a serum pregnancy test prior to administration
- Avoid during pregnancy unless potential benefit to the patient outweighs potential risk to the fetus
- Adverse developmental outcomes observed in 3 animal species at clinically relevant doses raise concerns about potential adverse developmental outcomes in humans
Contraindications
Hypersensitivity
Use of intravenous unfractionated heparin sodium
Cautions
New onset or worsening renal impairment has been reported (monitor renal function)
Efficacy decreased with moderate-to-severe baseline renal impairment (ie, CrCl <50 mL/min) for skin and skin structure infections
Administer over at least 1 hr to minimize infusion-related adverse reactions
Clostridium difficile-associated diarrhea may occur
May prolong QTc interval; coadministration with other drugs that prolong QTc interval (eg, phenothiazine, TCAs, macrolide antibiotics, class I and III antiarrhythmic agents) increased risk for life-threatening arrhythmias
Interferes with coagulation tests including PT, INR, and APT, but does not interfere with coagulation
Pregnancy & Lactation
Pregnancy
There is a pregnancy registry that monitors pregnancy outcomes in women exposed to therapy during pregnancy; physicians are encouraged to register pregnant patients, or pregnant women may enroll themselves in the VIBATIV pregnancy registry by calling 1-877-484-2700
There are no available data on therapy use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; based on findings in animal reproduction studies, drug may cause fetal harm; advise pregnant women of potential risk to fetus; estimated background risk of major birth defects and miscarriage for indicated population is unknown
In embryo-fetal development studies in rats, rabbits, and minipigs, telavancin demonstrated potential to cause limb and skeletal malformations when given intravenously during the period of organogenesis at doses providing approximately 1- to 2-fold the human exposure at maximum recommended clinical dose
Verify pregnancy status in females of reproductive potential prior to initiating therapy
Contraception
- Females:Therapy may cause fetal harm when administered to a pregnant woman; advise females of reproductive potential to use effective contraception during treatment and for 2 days after final dose
Infertility
- Males: Based on findings in rats, therapy may impair male fertility; effect on fertility was reversible in rats
Lactation
There are no data on presence of telavancin in human milk, effects on breastfed child, or on milk production; developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal conditions
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Lipoglycopeptide antibiotic that is a synthetic derivative of vancomycin
Inhibits bacterial cell wall synthesis by interfering with polymerization and cross-linking of peptidoglycan
Unlike vancomycin, telavancin also depolarizes the bacterial cell membrane and disrupts its functional integrity
Absorption
Poor oral absorption
Distribution
Protein Bound: 90%
Vd: 133-145 mL/kg
Metabolism
Metabolic pathway not yet identified; not metabolized by CYP450 isoenzymes
Elimination
Half-life: 8 hr
Clearance: 13.1-13.9 mL/hr/kg
Excretion: 75% urine; <1% feces
Administration
IV Compatibility
Data limited
Do not add other drugs or infuse simultaneously through same IV line
Flush IV line before and after infusion for sequential infusion of additional medications
IV Preparation
750 mg vial reconstitution
- Reconstitute lyophilized powder by adding 45 mL of D5W, SWI, or 0.9% NaCl
- Resultant solution concentration 15 mg/mL (total volume ~50 mL)
Further dilution
- Solutions for further dilution before infusion include: D5W, 0.9% NaCl, lactated Ringer's injection
- Doses of 150-800 mg: dilute further in 100-250 mL of IV solution
- Doses <150 mg or >800 mg: dilute further to final concentration of 0.6-8 mg/mL
IV Administration
Intermittent IV infusion over 60 min
Storage
No preservative or bacteriostatic agent in product
Unopened vials
- Refrigerate at 2-8°C (35-46°F); excursions to ambient temperatures (up to 25°C [77°F]) are acceptable
- Avoid excessive heat
Reconstituted solution or further diluted
- Stored at room temperature: Use within 4 hr
- Stored refrigerated: Use within 72 hr
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Vibativ intravenous - | 750 mg vial |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
telavancin intravenous
TELAVANCIN - INJECTION
(TEL-a-VAN-sin)
COMMON BRAND NAME(S): Vibativ
WARNING: Adults with moderate to severe kidney disease who are using telavancin to treat serious lung infections may be at an increased risk for death. Discuss the risks and benefits of this medication, as well as other effective and possibly safer treatments for lung infections, with your doctor.Telavancin may cause or worsen kidney problems. Problems are more likely to occur if you have heart failure, kidney disease, diabetes, or high blood pressure, or if you take certain medications (see also Drug Interactions section). Kidney function tests must be performed before you start treatment, during treatment, and after you finish treatment to check for kidney problems. Tell your doctor right away if you have any signs of kidney problems such as a change in the amount of urine.Tell your doctor if you are pregnant or plan to become pregnant. Your doctor may order a pregnancy test before starting this medication. You should not become pregnant while using telavancin. Telavancin may harm an unborn baby. Women of childbearing age should ask about reliable forms of birth control while using this medication and for 2 days after the last dose. If you become pregnant, talk to your doctor right away about the risks and benefits of this medication.
USES: This medication is an antibiotic used to treat serious bacterial infections of the skin and certain types of pneumonia. It works by stopping the growth of bacteria.
HOW TO USE: Read the Medication Guide provided by your pharmacist before you start using telavancin and each time you get a refill. If you have any questions, ask your doctor or pharmacist.This medication is given by injection into a vein as directed by your doctor, usually once a day. It should be injected slowly over 60 minutes. The dosage and length of treatment is based on your weight, medical condition, and response to treatment.If you are giving this medication to yourself at home, learn all preparation and usage instructions from your health care professional. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Learn how to store and discard medical supplies safely.For the best effect, use this antibiotic at evenly spaced times. To help you remember, use this medication at the same time(s) every day.Continue to use this medication until the full prescribed amount is finished, even if symptoms disappear after a few days. Stopping the medication too early may allow bacteria to continue to grow, which may result in a return of the infection.Tell your doctor if your condition lasts or gets worse.
SIDE EFFECTS: See also Warning section.Flushing of the upper body may occur if this medication is injected too fast ("red man syndrome"). Tell your doctor right away if this occurs. The infusion of this medication may need to be slowed or stopped.Metallic/soapy taste, nausea, vomiting, or foamy urine may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Get medical help right away if you have any very serious side effects, including: fast/irregular heartbeat, severe dizziness, fainting.This medication may rarely cause a severe intestinal condition due to a bacteria called C. difficile. This condition may occur during treatment or weeks to months after treatment has stopped. Tell your doctor right away if you develop: diarrhea that doesn't stop, abdominal or stomach pain/cramping, blood/mucus in your stool.If you have these symptoms, do not use anti-diarrhea or opioid products because they may make symptoms worse.Use of this medication for prolonged or repeated periods may result in oral thrush or a new vaginal yeast infection. Contact your doctor if you notice white patches in your mouth, a change in vaginal discharge, or other new symptoms.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any of the following symptoms of a serious allergic reaction: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: See also Warning section.Before using telavancin, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history.Telavancin may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can rarely cause serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that need medical attention right away.The risk of QT prolongation may be increased if you have certain medical conditions or are taking other drugs that may cause QT prolongation. Before using telavancin, tell your doctor or pharmacist of all the drugs you take and if you have any of the following conditions: certain heart problems (heart failure, slow heartbeat, QT prolongation in the EKG), family history of certain heart problems (QT prolongation in the EKG, sudden cardiac death).Low levels of potassium or magnesium in the blood may also increase your risk of QT prolongation. This risk may increase if you use certain drugs (such as diuretics/"water pills") or if you have conditions such as severe sweating, diarrhea, or vomiting. Talk to your doctor about using telavancin safely.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Telavancin may cause live bacterial vaccines (such as typhoid vaccine) to not work well. Tell your health care professional that you are using telavancin before having any immunizations/vaccinations.Older adults may be more sensitive to the side effects of this drug, especially QT prolongation (see above).During pregnancy, this medication should be used only when clearly needed. It may harm an unborn baby. Consult your doctor for more details. (See also Warning section.)It is unknown if this medication passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: other drugs that may affect the kidneys (including NSAIDs such as ibuprofen), "blood thinners" (such as heparin).This medication may interfere with certain lab tests (such as coagulation tests such as PT/INR/APPT, urine protein tests), possibly causing false test results. Make sure lab personnel and all your doctors know you use this drug.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: See also Warning section.Lab and/or medical tests (such as kidney function) may be done while you are using this medication. Keep all medical and lab appointments. Consult your doctor for more details.
MISSED DOSE: It is important to get each dose of this medication as scheduled. If you miss a dose, ask your doctor or pharmacist right away for a new dosing schedule. Do not double the dose to catch up.
STORAGE: Consult the product instructions and your pharmacist for storage details. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised July 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
